- LIVE QUOTES
- LEARN
- HELP
More from Webull
Our Partners
Nasdaq
Wall Street JournalEN
M
MXCT
Maxcyte
0.74
0.01+0.93%After Hours: 0.7394 0.00 0.00%19:37 02/20 EST
OPEN/PREV CLOSE0.7409/0.7326
TODAY RANGE0.7114-0.7564
VOL1.16M
MARKET CAP78.87M
52 WEEK RANGE0.6434-4.210
AVG VOL (3M)1.17M
% TURNOVER1.09%
TURNOVER--
P/E (TTM)-1.7203
% RANGE6.14%
EPS(TTM)-0.4298
P/E(FORWARD)-1.8485
P/B0.4374
BVPS1.690
DIVIDEND--
P/S2.024
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP73.77M
SHARES OUTSTANDING106.67M
NEXT EARNINGS03/02-03/15
FREE FLOAT99.77M
LOT SIZE1
EX-DATE--
News
Press Releases
Financial Reports
Profile
Reuters·01/12 21:46
MaxCyte Expects Core Revenue of Up to $29.6 Million for 2025
Seeking Alpha·01/12 13:16
MaxCyte sees Q4 core revenue between $6.6M and $6.7M
TipRanks·01/12 13:15
MaxCyte sees Q4 core revenue $6.6M-$6.7M, consensus $9.3M
Dow Jones·01/12 13:11
*MaxCyte Sees FY25 Core Rev $29.5M - $29.6M >MXCT
Dow Jones·01/12 13:10
*MaxCyte Sees 4Q Core Rev $6.6M - $6.7M >MXCT
Reuters·01/12 13:05
MAXCYTE INC <MXCT.O> Q4 REV VIEW $9.4 MLN -- LSEG IBES DATA
TipRanks·12/02/2025 18:55
MaxCyte management to meet with Craig-Hallum
Seeking Alpha·11/13/2025 10:48
MaxCyte reports Q3 results
Seeking Alpha·11/13/2025 00:12
MaxCyte outlines $17M–$19M annualized savings through restructuring while reiterating SPL revenue guidance
Dow Jones·11/12/2025 23:36
MaxCyte CFO Douglas Swirsky to Leave Post in 2026
Dow Jones·11/12/2025 23:10
*MaxCyte CFO Douglas Swirsky to Transition From Role in 1H of 2026
TipRanks·11/12/2025 22:20
MaxCyte CFO Douglas Swirsky to transition out of role
TipRanks·11/12/2025 22:05
MaxCyte reiterates FY25 revenue guidance flat to down 10% vs. last year
Seeking Alpha·11/12/2025 21:34
MaxCyte CFO to step down in first half of 2026
Same Industry
Name/Symbol
Change%
Price